SANOFI PASTEUR
- Country
- 🇫🇷France
- Ownership
- Subsidiary
- Established
- 1990-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.sanofipasteur.com
Clinical Trials
424
Trial Phases
5 Phases
Drug Approvals
34
Drug Approvals
Diphtheria, tetanus, pertussis (acellular, component), poliomyelitis (inactivated) vaccine and Haemophilus type b conjugate vaccine, adsorbed
- Product Name
- 潘太欣
- Approval Number
- 国药准字SJ20150034
- Approval Date
- Aug 13, 2020
Diphtheria, tetanus, pertussis (acellular, component), poliomyelitis (inactivated) vaccine and Haemophilus type b conjugate vaccine, adsorbed
- Product Name
- 潘太欣
- Approval Number
- 国药准字SJ20150033
- Approval Date
- Aug 13, 2020
Haemophilus Type b Conjugate Vaccine
- Product Name
- 安尔宝
- Approval Number
- 国药准字J20140173
- Approval Date
- May 25, 2020
Haemophilus Type b Conjugate Vaccine
- Product Name
- 安尔宝
- Approval Number
- S20140013
- Approval Date
- Apr 12, 2020
Haemophilus Type b Conjugate Vaccine
- Product Name
- 安尔宝
- Approval Number
- S20140014
- Approval Date
- Apr 12, 2020
POLIOMYELITIS VACCINE (INACTIVATED)
- Product Name
- 爱宝惟
- Approval Number
- 国药准字J20140171
- Approval Date
- Sep 16, 2019
POLIOMYELITIS VACCINE (INACTIVATED)
- Product Name
- 爱宝惟
- Approval Number
- S20140062
- Approval Date
- Aug 8, 2019
POLIOMYELITIS VACCINE (INACTIVATED)
- Product Name
- 爱宝惟
- Approval Number
- S20140063
- Approval Date
- Aug 8, 2019
Clinical Trials
Distribution across different clinical trial phases (375 trials with phase data)• Click on a phase to view related trials
Phase 3 Single Arm, Open Study on vYF in Adults
- Conditions
- Yellow Fever
- Interventions
- Biological: Yellow fever vaccine (live)
- First Posted Date
- 2025-10-29
- Last Posted Date
- 2025-11-03
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 254
- Registration Number
- NCT07222059
- Locations
- 🇯🇵
Investigational Site Number : 3920001, Takatsuki, Osaka, Japan
🇯🇵Investigational Site Number : 3920002, Chūō, Tokyo, Japan
🇯🇵Investigational Site Number : 3920003, Shinjuku-ku, Tokyo, Japan
Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Participants With Mild Acne
- First Posted Date
- 2025-06-10
- Last Posted Date
- 2025-09-05
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 120
- Registration Number
- NCT07013747
- Locations
- 🇺🇸
Moore Clinical Research - Brandon- Site Number : 8400007, Brandon, Florida, United States
🇺🇸Encore Research Group-Jacksonville Center for Clinical Research- Site Number : 8400006, Jacksonville, Florida, United States
🇺🇸Encino Research Center- Site Number : 8400008, Encino, California, United States
Post-marketing Surveillance Study for the Safety of a DTaP-IPV- HB-PRP~T Vaccine in Republic of Korea
- Conditions
- Hepatitis BHaemophilus Influenzae Type b Immunisation
- Interventions
- Biological: DTaP-IPV-Hep B-PRP-T combined vaccine
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 690
- Registration Number
- NCT06793826
- Locations
- 🇰🇷
Investigational Site Number : 002, Cheonan, Korea, Republic of
🇰🇷Investigational Site Number : 001, Seoul, Korea, Republic of
Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents
- Conditions
- Pneumococcal Infections
- Interventions
- Biological: 20vPCV
- First Posted Date
- 2025-02-20
- Last Posted Date
- 2025-10-06
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 1268
- Registration Number
- NCT06838000
- Locations
- 🇺🇸
Site # 8400008, Paramount, California, United States
🇺🇸Site # 8400024, Doral, Florida, United States
🇺🇸Site # 8400007, Hialeah, Florida, United States
Repeated Cross Sectional Surveillance Study To Determine the Respiratory Syncytial Virus (RSV) Immunization Rates in German Infants
- Conditions
- Respiratory Syncytial Virus Immunization
- First Posted Date
- 2025-02-13
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 2400
- Registration Number
- NCT06824207
- Prev
- 1
- 2
- 3
- 4
- 5
- 75
- Next
News
Saint Louis University Launches Phase 1 Trial for Investigational West Nile Virus Vaccine
Saint Louis University's Center for Vaccine Development will enroll up to 30 healthy adult volunteers in a Phase 1 clinical trial to evaluate the safety and immune response of an updated investigational West Nile virus vaccine.